Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid

Inclusion Criteria: * Molecularly characterised patients with a known mutation of their LMNA gene leading to the production of a farnesylated prelamin A, whether truncated or not * Patients must be able to travel and consult in Marseille, France for necessary explorations planned at the inclusion step, then following the protocol flow * chart for zoledronic acid injections and follow-up visits * Patient older than 3 years * Patients affiliated or beneficiary of a legal medical insurance * Adult patients certifying they have been properly informed about the protocol, and they signed a written consent form. Children and/or disabled patients whose parents/legal tutor have been informed and have signed a written consent form Exclusion Criteria: * Known hypersensitivity to pravastatin or zoledronic acid * Seric transaminase levels higher than 3 times of normal value * CPK level higher than 5 times of normal value * Creatininemia higher than 0.5mg/dl or 44mM, or creatinin clearance lower than 70ml/min/1.73m3 * Presence of dental troubles, or recent dental trouble * Maxillary osteonecrosis or bone nakedness antecedent * Congenital galacosemia, glucose or galactose maladsorption syndrome, lactase deficiency * Every other pathology thought to be incompatible with proposed treatment by the investigator * Under treatment that can interfere with pravastatin and/or zoledronate metabolisms